Key Highlights

  • Baird Medical (NASDAQ:BDMD) fell 20.94% to USD 0.1091, even with a China distribution agreement.
  • PAVmed (NASDAQ:PAVM) rose 9.95% to USD 2.10, and no explaining announcement was identified.
  • Innovative Eyewear (NASDAQ:LUCY) slipped 9.75% to USD 0.75, with no catalyst identified.
  • Rockwell Medical (NASDAQ:RMTI) gained 11.04% to USD 7.67, following a Vantive deal.
  • TriSalus (NASDAQ:TLSI) declined 15.70% to USD 3.06, with no announcement identified.
  • Bioventus (NASDAQ:BVS) dropped 19.47% to USD 10.59, following third quarter results.

Baird Medical (NASDAQ:BDMD) (down USD 0.0289, 20.94%): Lower Even With a Distribution Deal

Baird Medical Investment Holdings (NASDAQ:BDMD) fell 20.94% to USD 0.1091 in pre-market trading on November 3, 2026. On November 2, 2026, it announced an exclusive agreement with a China Resources Pharmaceutical Group Subsidiary covering 19 key markets in China, with an initial order of about RMB 6 million, roughly USD 900,000.

No announcement explaining the drop itself was identified. As a penny stock, thin Liquidity and dilution risk can magnify swings.

PAVmed (NASDAQ:PAVM) (up USD 0.1900, 9.95%): Looking Ahead to the November 13 Call

PAVmed (NASDAQ:PAVM) rose 9.95% to USD 2.10 in pre-market trading on November 3, 2026. No announcement explaining the jump was identified. Its October 30, 2026 release only scheduled a third quarter Business update call for November 13, 2026.

Cash stood at USD 3.8 million on June 30, 2026, against six-month operating expenses of USD 15.1 million, so the company relies on raising funding. Calculated from those figures, cash covers roughly one quarter of spending at the first-half pace.

Innovative Eyewear (NASDAQ:LUCY) (down USD 0.0810, 9.75%): Lower Despite a Record Sales Update

Innovative Eyewear (NASDAQ:LUCY) slipped 9.75% to USD 0.75 in pre-market trading on November 3, 2026. No announcement dated October 30 to November 3, 2026 was identified as a catalyst.

Preliminary third quarter net sales were about USD 1.04 million, up about 55%, although the figures are unaudited and could change. The release listed the ability to obtain additional financing and to continue as a Going Concern among its risk factors. As a penny stock, it carries Volatility and dilution risk.

Rockwell Medical (NASDAQ:RMTI) (up USD 0.7626, 11.04%): A Dialysis Business Purchase

Rockwell Medical (NASDAQ:RMTI) gained 11.04% to USD 7.67 in pre-market trading on November 3, 2026. It signed a definitive agreement to purchase Vantive's hemodialysis concentrates, monitors and water treatment systems, excluding dialyzers.

The deal is expected to close in mid-2027, subject to regulatory approvals. The price was not disclosed, and cash and investments stood at USD 24.8 million on June 30, 2026, so any share issuance could dilute holders. Third quarter results are due November 12, 2026.

TriSalus (NASDAQ:TLSI) (down USD 0.5699, 15.70%): A Decline With No New Headline

TriSalus Life Sciences (NASDAQ:TLSI) fell 15.70% to USD 3.06 in pre-market trading on November 3, 2026. No company announcement dated November 2 or 3, 2026 was identified, and no trigger can be confirmed.

Second quarter Revenue was USD 11.4 million, up 1.7%, while full-year guidance of USD 54 million to USD 57 million was kept in place, so the second half carries much of the load. Cash was USD 46.3 million against long-term Debt of USD 33.1 million, and the company flagged Credit Facility covenant risk.

Bioventus (NASDAQ:BVS) (down USD 2.56, 19.47%): Down Following Third Quarter Results

Bioventus (NASDAQ:BVS) dropped 19.47% to USD 10.59 in pre-market trading on November 3, 2026, after its November 2, 2026 report. Net sales came in at USD 142.4 million, up 2.7%, and adjusted EBITDA rose to USD 28.4 million.

The company continues to review strategic alternatives, which may or may not lead to a transaction. Restorative Therapies sales fell 3.4%, and U.S. sales grew only 1.0%. Cash was USD 30.7 million on September 26, 2026.

Overall View

Only Baird Medical, Rockwell Medical and Bioventus had company news tied to the session, and the steepest declines came from Baird Medical and Bioventus. PAVmed, Innovative Eyewear and TriSalus moved without an identified announcement. Items to watch include the PAVmed call on November 13, Rockwell Medical results on November 12, mid-November reports from Innovative Eyewear and any strategic review update from Bioventus.